Figure 2.

 Adoptive transfer of lymphocytes genetically engineered to express MAGE‐A4‐specific T‐cell receptor inhibits human tumor progression in non‐obese diabetic/SCID/γc^null mice. Non‐obese diabetic/SCID/γc^null mice (n = 4 per group) were subcutaneously inoculated with 2.5 × 10⁶ KE4 (A–C) or QG56 (D) tumor cells, and intravenously administered ∼1 × 10⁸ gene‐modified (■) or unmodified (▴) cells or PBS alone (control, ○) on day 0. Total of 9 × 10⁶ (A,D), 3 × 10⁶ (B), or 1 × 10⁶ (C) tetramer⁺CD8⁺ cells were confirmed to be adoptively transferred; we subsequently monitored tumor growth over time. (E) Non‐obese, diabetic/SCID/γc^null mice (n = 4 per group) received the treatment 3 days after the subcutaneous inoculation of 2.5 × 10⁶ KE4. Total of 9 × 10⁶ tetramer⁺CD8⁺ cells were transferred. Mean tumor size for each group is represented as the average + SD of four mice. Results are representative of three independent experiments. Differences between groups were examined for statistical significance using the Student’s t‐test. *P < 0.01. Numerical value indicates the number of tetramer⁺CD8⁺ cells administrated.